Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Consuming higher amounts of omega-3 fatty acids does not appear to lower heart disease risk for women with type 1 diabetes, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

Female patients have fewest complications, shortest hospital stays after gastric bypass surgery: Study

A study of nearly 38,000 patients found Caucasian, Hispanic and female patients have the fewest complications and the shortest hospital stays after laparoscopic gastric bypass surgery, according to University of Nebraska Medical Center researchers who presented their findings today at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

25 Jun 2010

Medical weight loss programs before bariatric surgery show no clinical benefit

Patients required by their health insurance providers to complete a six-month medical weight loss program before bariatric surgery do no better than patients who have no such requirement, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

25 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patients who were denied bariatric surgery for insurance reasons developed a slew of new obesity-related diseases and conditions within three years of follow-up, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

24 Jun 2010

Patient health and safety initiatives to be highlighted at ADA annual conference

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, will highlight leading patient health and safety initiatives during the 70th annual American Diabetes Association Annual Conference June 26-28 in Orlando, FL.

From Roche Sequencing and Life Science 24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Debiotech and STMicroelectronics today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida.

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Children of mothers whose blood glucose (sugar) was high during pregnancy are more likely to have low insulin sensitivity—a risk factor for type 2 diabetes—even after taking into consideration the children's body weight, a new study shows. The results will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

23 Jun 2010

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

For individuals 65 years of age and older, obesity, excess body fat around the waist and gaining weight after the age of 50 are associated with an increased risk of diabetes, according to a study in the June 23/30 issue of JAMA.

23 Jun 2010

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

Female patients have fewest complications, shortest hospital stays after gastric bypass surgery: Study

Medical weight loss programs before bariatric surgery show no clinical benefit

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patient health and safety initiatives to be highlighted at ADA annual conference

Spherix to explore triglycerides for D-tagatose therapy

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in